Takeaways: Shortening Breyanzi’s required stay-near-centre period and driving ban lowers the logistical and financial barriers to CAR T, which should modestly expand the eligible treat...
Contract development and manufacturing organizations, often referred to as CDMOs, were once viewed primarily as outsourced service providers supporting pharmaceutical production. Today, their role is ...
Rare diseases were once considered commercially unattractive due to their limited patient populations and high development costs. Today, however, they have become one of the fastest growing areas of i...
Sustainability in the pharmaceutical industry is evolving beyond environmental, social, and governance reporting into a broader strategic priority. What was once viewed primarily as a corporate respon...
Cell and gene therapies are redefining the future of medicine, offering the possibility of long term remission and even cures for diseases once considered untreatable. Yet despite this scientific prom...
The global biopharma industry is facing intensifying scrutiny over drug pricing as governments and payers push back against rising healthcare costs. In Canadian Health systems, where public funding pl...
